ReviewInfection2021
Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence.
Review in Infection, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.
- Cost-effectiveness of remdesivir for the treatment of hospitalized patients with COVID-19: a systematic review.Infectious diseases of poverty · 2023Pooled it
- On the ozonation of anti-SARS-CoV-2 substances and their nucleoside analogues for mechanistic understanding of the ozone induced transformation using HPLC-ESI-Q-TOF-HRMS.RSC advances · 2026Article
- Adverse drug reactions associated with COVID-19 management.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Clinical outcomes and considerations in outpatient with COVID-19 receiving remdesivir therapy.Health science reports · 2024Article
- Combined prevention and treatment measures are essential to control nosocomial infections during the COVID-19 pandemic.World journal of virology · 2024Article
- Clinical Course and Factors Associated With Hospital Admission and Mortality among Sars-Cov 2 Patients within Nairobi Metropolitan Area.medRxiv : the preprint server for health sciences · 2024Article
- Efficacy of host cell serine protease inhibitor MM3122 against SARS-CoV-2 for treatment and prevention of COVID-19.Journal of virology · 2024Article
- After the Hurricane: Anti-COVID-19 Drugs Development, Molecular Mechanisms of Action and Future Perspectives.International journal of molecular sciences · 2024Review
- A community effort in SARS-CoV-2 drug discovery.Molecular informatics · 2024Article
- Managing Infection Complications in the Setting of Chimeric Antigen Receptor T cell (CAR-T) Therapy.Clinical hematology international · 2024Review
- Article
- Outcomes of high-risk adult outpatients treated with early remdesivir therapy during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron era: experiences from the national centre of Hungary.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- COVID-19 in Patients with Pre-Existing Interstitial Lung Disease: Potential Value of a Steroid-Based Treatment Strategy.Journal of clinical medicine · 2023Article
- In Silico Discovery of Small-Molecule Inhibitors Targeting SARS-CoV-2 Main Protease.Molecules (Basel, Switzerland) · 2023Article
- Real-world use of remdesivir for the treatment of patients admitted to Italian hospitals with COVID-19: the nationwide retrospective FADOI-RECOVER study.BMC infectious diseases · 2023Observational
- Clinically Evaluated COVID-19 Drugs with Therapeutic Potential for Biological Warfare Agents.Microorganisms · 2023Review
- Severe COVID-19: Drugs and Clinical Trials.Journal of clinical medicine · 2023Review
- Article
- An Enhanced Dissolving Cyclosporin-A Inhalable Powder Efficiently Reduces SARS-CoV-2 Infection In Vitro.Pharmaceutics · 2023Article
- In silico investigation ofJournal of ginseng research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is an infectious disease caused by a novel β-coronavirus, belonging to the same subgenus as the Severe Acute Respiratory Syndrome (SARS) virus. Remdesivir, an investigational broad-spectrum antiviral agent has previously demonstrated in vitro activity against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and in vivo efficacy against other related coronaviruses in animal models. Its safety profile has been tested in a compassionate use setting for patients with COVID-19. The current therapeutic studies demonstrate clinical effectiveness of remdesivir in COVID-19 patients by shortening time to clinical recovery, and hospital stay. In this review, we critically analyze the current evidence of remdesivir against COVID-19 and dissect the aspects over its safety and efficacy. Based on existing data, remdesivir can be regarded as a potential therapeutic agent against COVID-19. Further large-scale, randomized placebo-controlled clinical trials are, however, awaited to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.